SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Gold/Mining/Energy : Inflazyme Pharmaceuticals (T.IZP)

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Amanda Marley-Clarke who wrote (1270)7/13/1999 6:49:00 PM
From: Sean Janzen  Read Replies (1) of 1501
 
Amanda,

Where are you getting the figure 69 million shares outstanding?

If you haven't already read IZP's prospectus then you should. You can find directions at this site: Message 10295016

For information on shares outstanding go to page 6. As of mid June/99.

Common Shares.....32,004,628
Preferred Shares....11,185,814
Warrants.................4,664,377
Options...................2,237,000
-------------------------------
Fully Diluted.........46,413,263 (1)

Note:
(1) Up to 7,507,258 common shares are issuable upon conversion of the 11,185,814 preferred shares Series 1, issued to HMR.

Mr. McBeath stated in yesterdays release that the conversion of HMR's preferred shares might occur 2 or 3 years hence. Lets hope IZP can generate enough interest to pump the share price over $9. Canadian thus minimize any dilution.

Also important to note, HMR's preferred shares will nearly double as IZP draws on the funds remaining. The nearly 22,000,000 preferred share will translate into a maximum of approximately 15 million common shares. If IZP trades over $9 at the time of conversion then HMR will receive slightly under 3 million common shares.

I hope I have this correct.

Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext